Want to see HK:2269 full AI Analyst Report?

Wuxi Biologics (Cayman) (2269) Price & Analysis

56 Followers

2269 Stock Chart & Stats

HK$35.72

HK$0.44(2.67%)

At close: Jan 09 4:00 PM EST

HK$35.72

HK$0.44(2.67%)

Day’s Range― - ―

52-Week RangeHK$24.50 - HK$44.00

Previous CloseN/A

Volume35.71M

Average Volume (3M)32.67M

Market Cap

HK$148.58B

Enterprise ValueHK$100.51B

Total Cash (Recent Filing)HK$15.74B

Total Debt (Recent Filing)HK$3.11B

Price to Earnings (P/E)26.1

Beta1.71

Next Earnings

Aug 26, 2026

EPS Estimate

0.68

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.19

Shares Outstanding4,143,356,400

10 Day Avg. Volume33,789,006

30 Day Avg. Volume32,668,415

Financial Highlights & Ratios

PEG Ratio0.53

Price to Book (P/B)2.53

Price to Sales (P/S)5.48

P/FCF Ratio42.67

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$49.32

Price Target Upside38.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)1.33

Revenue Forecast (FY)HK$25.24B

Bulls Say, Bears Say

Bulls Say

High ProfitabilitySustained high margins provide durable cash generation and pricing flexibility across client contracts. Healthy gross and EBIT margins support reinvestment in capacity and R&D, underpinning long-term competitiveness and ability to absorb pricing or mix shifts without immediate margin erosion.

Conservative Balance SheetVery low leverage gives the company long-term financial flexibility to fund capital expansion, weather client timing, or pursue strategic deals without pressuring interest coverage. This reduces default risk and supports steady investment in capacity to capture life-cycle outsourcing demand.

Integrated CRDMO ModelAn end-to-end CRDMO offering encourages client consolidation and sticky, fee-based revenue as programs progress from discovery to commercial supply. The breadth of services supports cross-selling, higher lifetime client value, and more predictable manufacturing revenues as customer programs mature.

Bears Say

Slowing Revenue GrowthA clear deceleration in top-line momentum reduces visibility on future capacity utilization and long-term margin expansion. Slower contract wins or slower program progress can compress throughput, delay move to higher-margin commercial manufacturing, and lengthen payback on facility investments.

Weak Cash ConversionFCF materially trailing net income and historical FCF volatility indicate earnings are less reliably convertible to cash, driven by capex and working capital swings. This constrains self-funding for capacity builds or M&A and raises reliance on external financing during investment cycles.

Returns Below PeakROE and margins lag prior peaks, suggesting lasting pressure from mix, pricing, or cost base increases. If structural factors (competition, lower pricing for commoditized services, or higher fixed costs) persist, the company may face slower improvement in capital returns despite scale.

Wuxi Biologics (Cayman) News

WuXi Biologics Wins Full Shareholder Backing at 2026 AGM

Wuxi Biologics (Cayman) ( ($HK:2269) ) has provided an update. WuXi Biologics said shareholders approved all resolutions at...

24d ago

Wuxi Biologics Grants Time-Based Restricted Shares to 21 Employees

Wuxi Biologics (Cayman) ( ($HK:2269) ) has issued an update. Wuxi Biologics has approved the grant of 288,441...

25d ago

WuXi Biologics Schedules 2026 Business Update Calls for Investors

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an update. WuXi Biologics has announced that it will host...

1M ago

WuXi Biologics Launches US$400 Million Share Buyback Plan

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an update. WuXi Biologics has resolved to activate its shareholder-approved...

1M ago

WuXi Biologics Sets 2026 AGM to Vote on Board, Auditors and New Share Mandate

The latest update is out from Wuxi Biologics (Cayman) ( ($HK:2269) ). WuXi Biologics (Cayman) Inc. has called...

2M ago

WuXi Biologics: Robust Backlog, High-Margin Growth Drivers, and Capacity Expansion Underpin Buy Rating

CMB International Securities analyst Jill Wu maintained a Buy rating on Wuxi Biologics (Cayman) today and set a...

3M ago

Wuxi Biologics Grants 25.6 Million Restricted Shares Under Incentive Scheme

Wuxi Biologics (Cayman) ( ($HK:2269) ) has issued an update. Wuxi Biologics has approved the grant of 25,575,356...

3M ago

WuXi Biologics Schedules Briefings on 2025 Annual Results for Global Investors

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an announcement. WuXi Biologics (Cayman) Inc., a Hong Kong-listed biologics...

3M ago

Wuxi Biologics Delivers Strong 2025 Profit Growth as Project Portfolio Expands

Wuxi Biologics (Cayman) ( ($HK:2269) ) has provided an announcement. Wuxi Biologics reported strong 2025 results, with revenue...

3M ago

WuXi Biologics Forecasts Strong 2025 Profit Growth on Expanded Services and Efficiency Gains

Wuxi Biologics (Cayman) ( ($HK:2269) ) has shared an update. WuXi Biologics (Cayman) Inc. has issued a positive...

5M ago

WuXi Biologics downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded WuXi Biologics to Neutral from Buy with a price target of HK$21.60, down from HK$50....

2y ago

GSK, WuXi Biologics enter into license agreement on TCE antibodies

WuXi Biologics (WXIBF) announced a license agreement with GSK plc (GSK) under which GSK will have exclusive licenses...

3y ago

GSK

2269 FAQ

What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?

Wuxi Biologics (Cayman) Inc. lowest stock price was HK$24.50 and its highest was HK$44.00 in the past 12 months.

What is Wuxi Biologics (Cayman) Inc.’s market cap?

Wuxi Biologics (Cayman) Inc.’s market cap is HK$148.58B.

When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?

Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Aug 26, 2026 which is in 53 days.

How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?

Wuxi Biologics (Cayman) Inc. released its earnings results on Mar 24, 2026. The company reported HK$0.68 earnings per share for the quarter, missing the consensus estimate of HK$0.728 by -HK$0.048.

Is Wuxi Biologics (Cayman) Inc. overvalued?

According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Wuxi Biologics (Cayman) Inc. pay dividends?

Wuxi Biologics (Cayman) Inc. does not currently pay dividends.

What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?

Wuxi Biologics (Cayman) Inc.’s EPS estimate is 0.68.

How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?

Wuxi Biologics (Cayman) Inc. has 4,143,356,400 shares outstanding.

What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?

Wuxi Biologics (Cayman) Inc. reported an EPS of HK$0.68 in its last earnings report, missing expectations of HK$0.728. Following the earnings report the stock price went up 4.568%.

Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?

Currently, no hedge funds are holding shares in HK:2269

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Wuxi Biologics (Cayman) Stock Smart Score

Neutral

Analyst Consensus

Strong Buy

Average Price Target:
HK$49.32 (38.06% Upside)

Technicals

Fundamentals

Return on Equity

10.64%

Trailing 12-Months

Asset Growth

16.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Wuxi Biologics (Cayman) Inc.

Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.

Wuxi Biologics (Cayman) (2269) Earnings & Revenues

Historic Earnings Reports

2269 Company Deck

2269 Earnings Call

Q4 2026

0:00 / 0:00

2269 Stock 12 Month Forecast

Average Price Target

HK$49.32

▲(38.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"HK$24","55":"HK$55","31.75":"HK$31.8","39.5":"HK$39.5","47.25":"HK$47.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54.49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$54.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.315,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$49.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,31.75,39.5,47.25,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.6,36.13,37.660000000000004,39.19,40.72,42.25,43.78,45.31,46.84,48.370000000000005,49.900000000000006,51.43000000000001,52.96,{"y":54.49,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.6,35.73192307692308,36.863846153846154,37.995769230769234,39.12769230769231,40.25961538461539,41.39153846153846,42.52346153846154,43.65538461538461,44.78730769230769,45.919230769230765,47.051153846153845,48.183076923076925,{"y":49.315,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.6,35.16923076923077,35.73846153846154,36.30769230769231,36.87692307692308,37.44615384615385,38.01538461538462,38.58461538461538,39.15384615384615,39.723076923076924,40.292307692307695,40.86153846153846,41.43076923076923,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.72,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.44,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.86,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.74,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.86,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.04,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.62,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >